Mom Residual Vs Qqq 60d
Mom Residual Vs Qqq 60d - a xsec_momentum concept routed into the paid catalog by lifetime ROR (non-HoF, ROR 10-25%). Lifetime ROR 12.7%, Sharpe 0.60, MaxDD -48.8% across the backtest window. Plain-text source code included.
Results are hypothetical and based on a historical backtest. Past performance does not guarantee future results. See risk disclosure for full details.
The backtest, in full.
Year-by-year, month-by-month.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | MaxDD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1994 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% | 0.0% |
| 1995 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% | 0.0% |
| 1996 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% | 0.0% |
| 1997 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% | 0.0% |
| 1998 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% | 0.0% |
| 1999 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% | 0.0% |
| 2000 | -10.3 | 42.2 | -14.6 | -15.2 | -13.6 | 2.3 | -0.6 | 14.4 | -3.7 | 0.9 | -12.9 | -0.7 | -24.0% | -48.5% |
| 2001 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% | 0.0% |
| 2002 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% | 0.0% |
| 2003 | 0.0 | 0.0 | 0.0 | 0.0 | 28.9 | -3.3 | 2.7 | 3.9 | -3.7 | 8.2 | -4.1 | -4.7 | 35.5% | -16.2% |
| 2004 | -0.7 | -0.0 | -6.7 | -2.8 | 2.2 | 4.4 | -10.1 | -0.6 | 2.9 | 6.3 | 12.8 | -0.8 | 11.7% | -21.9% |
| 2005 | -5.5 | 0.7 | -5.2 | -4.8 | 1.9 | -4.1 | -1.0 | 2.1 | 6.5 | 0.0 | 3.1 | 0.4 | -6.1% | -16.1% |
| 2006 | 9.6 | -5.2 | 10.8 | 0.0 | -10.7 | -2.2 | 0.9 | 2.8 | 7.5 | 1.6 | 5.4 | -1.1 | 21.3% | -19.3% |
| 2007 | 0.7 | -2.9 | -1.0 | 3.9 | 5.0 | 0.8 | 3.5 | 3.3 | 9.2 | 5.2 | -4.7 | 0.1 | 25.9% | -15.2% |
| 2008 | -17.2 | 4.2 | -1.9 | 0.4 | 6.3 | -10.3 | -1.3 | 0.7 | -0.8 | -0.8 | -0.5 | -0.2 | -23.0% | -22.1% |
| 2009 | 0.3 | -0.3 | 0.4 | 0.7 | 5.9 | -7.0 | 16.1 | 1.2 | 9.8 | -3.7 | 4.3 | 0.4 | 37.0% | -14.7% |
| 2010 | -10.7 | 2.3 | 4.9 | 7.2 | -11.2 | -2.5 | 5.0 | -0.7 | 5.2 | 3.3 | 0.8 | -2.6 | 16.1% | -15.2% |
| 2011 | 3.0 | 0.3 | -3.0 | 1.4 | -1.8 | 2.5 | -0.5 | -0.5 | -3.7 | 2.1 | 1.5 | -1.9 | -3.0% | -23.6% |
| 2012 | 5.5 | 5.8 | 2.3 | -4.0 | -12.4 | -1.1 | 1.2 | 1.6 | 1.9 | -0.8 | 2.3 | 3.4 | 8.7% | -20.5% |
| 2013 | 15.2 | 2.7 | 6.5 | 4.0 | 5.9 | -6.7 | 1.4 | 1.6 | 3.0 | -0.7 | 0.5 | 0.5 | 49.8% | -10.6% |
| 2014 | 3.0 | 13.4 | -4.7 | -2.8 | 8.7 | 4.4 | -4.8 | 6.4 | -2.3 | 9.8 | 7.4 | 1.5 | 40.4% | -12.7% |
| 2015 | -2.5 | 5.7 | -2.3 | 1.8 | 2.4 | -2.3 | 5.4 | -5.1 | -5.6 | 5.1 | 3.6 | -0.6 | 12.1% | -14.5% |
| 2016 | -12.6 | 2.8 | 0.5 | -2.2 | 0.1 | -0.9 | 7.6 | 6.2 | 6.4 | -5.8 | 9.0 | 2.0 | 8.0% | -15.7% |
| 2017 | 2.9 | -1.4 | 1.5 | 0.2 | 6.0 | -3.5 | 3.8 | -1.1 | -1.6 | 5.3 | -0.5 | -0.4 | 16.2% | -8.8% |
| 2018 | 9.8 | -1.2 | -3.5 | 0.6 | 4.3 | -0.4 | 0.0 | 2.9 | 1.3 | -7.0 | -0.6 | -1.2 | 4.9% | -10.8% |
| 2019 | 0.4 | 2.3 | 5.2 | 2.3 | -8.0 | 0.3 | -2.1 | 2.4 | -2.9 | 4.9 | 2.2 | 9.2 | 13.0% | -16.0% |
| 2020 | 3.8 | -6.5 | -11.0 | 10.9 | 5.9 | 5.4 | 9.5 | 13.3 | -7.2 | -4.3 | 14.0 | 8.0 | 62.8% | -34.0% |
| 2021 | 13.0 | -2.0 | -1.7 | 0.5 | -2.5 | 9.1 | 8.0 | 1.9 | -5.6 | 5.5 | -2.4 | -1.5 | 26.3% | -17.3% |
| 2022 | -13.7 | 9.8 | 0.1 | -5.6 | -1.5 | -0.2 | 0.6 | -0.1 | -0.3 | -0.0 | 0.0 | -0.3 | -17.4% | -24.4% |
| 2023 | 0.2 | -0.1 | 0.1 | -2.6 | 3.4 | 5.2 | 6.3 | 2.5 | -5.3 | -1.3 | 13.8 | 2.7 | 15.5% | -15.0% |
| 2024 | -0.6 | 4.5 | 4.0 | -6.7 | 11.5 | -1.4 | -7.5 | 4.0 | -0.3 | 2.2 | 9.4 | -0.1 | 11.5% | -23.2% |
| 2025 | 6.5 | -9.9 | -6.2 | -2.1 | 0.1 | 3.9 | 2.2 | -6.6 | 3.0 | 7.5 | -1.1 | 2.6 | -3.9% | -31.7% |
| 2026 | 6.1 | 3.0 | -7.7 | 11.3 | 27.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 47.8% | -14.7% |
| Mean Yr | 0.2 | 2.1 | -1.0 | -0.1 | 2.0 | -0.2 | 1.4 | 1.7 | 0.4 | 1.3 | 1.9 | 0.5 | 11.7% | -14.6% |
Year rows: Total = compound of the row's monthly returns. Mean Yr row: per-month cells are column means; Total is the arithmetic mean of annual totals (not compound-of-cells, so the two won't agree โ this is by design).
| Metric | Strategy | SPY |
|---|---|---|
| ROR (CAGR) | 12.69% | 8.28% |
| Sharpe Ratio | 0.60 | 0.45 |
| MAR Ratio | 0.26 | โ |
| Max Drawdown | -48.8% | -55.2% |
| Trades | 1,118 | 1 |
| Avg Exposure | 1.8% | 100% |
What this strategy does
Mom Residual Vs Qqq 60d is a xsec_momentum concept that emerged from our research pipeline and was routed into the storefront by its lifetime ROR (10-25%, paid tier; non-HoF). It trades the Nasdaq-100 with point-in-time membership data, so the published numbers are survivorship-bias-free.
Why this tier
Basic is the entry tier: lifetime ROR at or below 17%, still inside the paid 10-25% routing band. Same .rts source and documentation as the higher tiers. Lifetime ROR 12.7%, Sharpe 0.60, MAR 0.26, MaxDD -48.8% across approximately 26 years (per-concept window pending).
What you get
Three files: the plain-text RealTest .rts source, a README with install steps and the Norgate data requirements, and your single-user license. The .rts is fingerprinted at delivery so the file is traceable to your purchase - no DRM, no subscription, no recurring fees.
- mom_residual_vs_qqq_60d.rtsRealTest strategy file (plain-text source)
- README.txtStrategy summary, install steps, Norgate data requirements, support contact
- LICENSE.txtSingle-user license, watermarked at delivery with your purchase fingerprint
Full plaintext .rts source delivered after purchase.
- Style
- Quantitative
- Universe
- Nasdaq-100 Current & Past Members
- Timeframe
- Daily
- Side
- Long
- Entry
- Mixed (see .rts)
- Exit
- Mixed (see .rts)
- Commission
- $0.005 / Share (IBKR Pro tier)
- Slippage
- $0.01 / Share
- Limit Buffer
- 0.05% past limit
- Risk-Free Rate
- Per-strategy (see .rts)
SPY Buy & Hold benchmark does not include transaction fees, slippage, or management costs. Strategy figures include both.
Backtests use daily-resolution OHLC data (Norgate does not provide intraday). Stops and limits are checked against the day's High/Low; same-day stop-and-target collisions are resolved pessimistically. See Risk Disclosure ยงย 11 for full detail.
- Data source
- Norgate Data Platinum - point-in-time Nasdaq-100 membership
- Backtest period
- 2000-01-03 to 2026-05-23
- Initial capital
- $100,000.00 USD
- Position sizing
- Per-strategy sizing documented in the .rts. Equal-weight default unless overridden.
- Compounding
- Compounded
- Survivorship bias
- None - Norgate's point-in-time membership and delisted symbols are both included in the backtest universe.
- Look-ahead bias
- None - signals computed at prior-day close. Entries fire at next-day open or as a same-day limit.
- Benchmark
- S&P 500 ETF (SPY) buy & hold
- Delivery
- RealTest v3.x .rts file + research include
| Item | Cost |
|---|---|
Mom Residual Vs Qqq 60d strategy What you're buying here | $99.00 USD one-time |
RealTest license Perpetual use of current version + 12 months of updates. Optional $159.00 USD/yr extension after that. mhptrading.com/purchase.html | $389.00 USD (one-time) |
Norgate Data US Stocks Platinum Required tier for point-in-time NDX membership back to 1990. No monthly plan. norgatedata.com/stockmarketpackages.php | $346.50 USD / 6 mo or $630.00 USD / 12 mo |
Broker commissions Modeled in backtest at IBKR Pro Fixed | ~$0.005 USD / share |
OrderClerk Only needed if you automate execution. No separate license cost. | Bundled with RealTest |
- 01Download the .zipClick your download link in the receipt email
- 02Open mom_residual_vs_qqq_60d.rts in RealTestFile -> Open
- 03Import symbolsClick Import (one-time, ~30 seconds with Norgate)
- 04Run the backtestClick Test - your numbers match the published numbers
Norgate Data US Stocks Platinum is required for the full backtest
Reproducing the published numbers needs survivorship-bias-free Nasdaq-100 history with point-in-time index membership and delisted securities. That is only available on Norgate's US Stocks Platinum subscription ($346.50 / 6 months or $630 / 12 months USD; no monthly plan). The free Norgate trial covers only a recent window - enough to confirm the strategy installs and runs, not enough to match the published equity curve.
RealTest is Windows-only
Mac or Linux users will need a Windows VM or dual-boot. RealTest does not run natively on macOS or Linux.
Drawdowns happen. The published MaxDD is real.
Maximum historical drawdown of -48.8% is from the backtest. Live trading drawdowns may exceed it. Size accordingly.
Inspectable proof, not promises.
Every claim in the Validation panel above is backed by a data artifact you can scrutinize. We publish the data behind the badges so a skeptical buyer can verify the strategy is genuinely robust, not a curve-fit that happens to clear our gates.
We resample the strategy's actual daily returns three different ways and rebuild the equity curve 2,000 times under each method. Each shaded band shows the range of paths the strategy could have produced under a different assumption about what the random variation looks like. The solid line is the production curve.
Reorders the daily returns with no replacement. Endpoint is identical for every path (compounding is commutative); only the path varies.
Resamples daily returns with replacement. Bands include sample-size uncertainty as well as path risk -- endpoint varies between paths.
Resamples in blocks of 20 consecutive days. Preserves short-term return clustering / autocorrelation -- most defensible for daily data with momentum/mean-reversion regimes.
The production trades landed in a slightly favorable order. Plan for somewhat deeper drawdowns than the backtest curve shows when trading live.
Common questions.
How do you decide what to sell?+
Why is the seller not trading this themselves?+
What is in the .zip?+
How can I reach support?+
Mom Residual Vs Qqq 60d -- $99.00 USD
One-time purchase. Instant download. Add 4+ strategies to your cart for a volume discount at checkout.
By purchasing you accept the Terms of Service, Privacy Policy, and Risk Disclosure.